DaVita Inc. Reports 5.2% Revenue Growth and 33.1% Net Income Increase in Q2 2026

DaVita Inc. reported a significant increase in financial performance for the second quarter of 2026, with total revenues reaching $3.55 billion, up from $3.38 billion in the same period last year, marking a 5.2% increase. The company's net income attributable to DaVita Inc. was $265.4 million, compared to $199.3 million in the prior year, reflecting a 33.1% rise. For the first half of 2026, total revenues were $6.97 billion, a 5.6% increase from $6.60 billion in the first half of 2025, while net income attributable to DaVita Inc. rose to $462.9 million from $362.3 million, a 27.7% increase.

The company experienced notable growth in its dialysis patient service revenues, which increased to $3.37 billion for the second quarter, up from $3.21 billion year-over-year. This growth was driven by an increase in treatment volumes and improved patient census, despite challenges such as higher missed treatment rates. Operating income for the second quarter was $579 million, up from $537.8 million in the previous year, indicating a 7.7% increase. The operating margin also improved, reflecting effective cost management and operational efficiencies.

Strategically, DaVita has been expanding its services, particularly in integrated kidney care (IKC), which provided services to approximately 64,900 patients in risk-based arrangements as of June 30, 2026. The company also completed the acquisition of a noncontrolling minority interest in Elara Caring, a home health services provider, for $200 million, which closed on July 20, 2026. This acquisition aligns with DaVita's strategy to broaden its service offerings beyond traditional dialysis.

Operationally, DaVita's total treatment volumes increased by 2.8% in the second quarter compared to the first quarter of 2026, with 7.23 million dialysis treatments performed. The company operated 2,671 dialysis centers in the U.S. as of June 30, 2026, an increase from 2,662 centers a year earlier. The company also reported a decrease in patient care costs per treatment, attributed to improved labor productivity and reduced pharmaceutical costs.

Looking ahead, DaVita anticipates continued growth driven by its strategic initiatives and operational efficiencies. The company expects to expand its offerings in middle molecule clearance treatments and maintain its focus on integrated kidney care. However, it remains cautious about external factors such as regulatory changes, economic conditions, and competitive pressures that could impact its operations and financial performance in the future.